5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.61▼ | 1.62▼ | 1.62▼ | 1.70▼ | 1.72▼ |
MA10 | 1.62▼ | 1.62▼ | 1.64▼ | 1.70▼ | 1.69▼ |
MA20 | 1.63▼ | 1.65▼ | 1.69▼ | 1.78▼ | 1.57▲ |
MA50 | 1.62▼ | 1.74▼ | 1.73▼ | 1.67▼ | 3.40▼ |
MA100 | 1.64▼ | 1.73▼ | 1.76▼ | 1.57▲ | 3.40▼ |
MA200 | 1.70▼ | 1.77▼ | 1.75▼ | 2.75▼ | 2.41▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | 0.003▲ | -0.009▼ | -0.027▼ | 0.146▲ |
RSI | 36.590▼ | 35.433▼ | 33.231▼ | 41.526▼ | 39.608▼ |
STOCH | 7.540▼ | 41.814 | 15.258▼ | 21.775 | 60.198 |
WILL %R | -71.429 | -90.000▼ | -95.000▼ | -100.000▼ | -44.898 |
CCI | -135.484▼ | -126.667▼ | -86.556 | -129.858▼ | 11.830 |
Friday, June 27, 2025 05:00 PM
Find the latest on short interest, settlement dates, average share volume, and days to cover for Outlook Therapeutics, Inc. Common Stock (OTLK) at Nasdaq.com.
|
Friday, June 27, 2025 02:57 PM
Live webcast on Wednesday, June 25th at 12:00 PM ETISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the ...
|
Friday, June 27, 2025 02:57 PM
Live webcast on Wednesday, June 25th at 12:00 PM ETISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/06/25 | 1.65 | 1.6894 | 1.60 | 1.60 | 597,249 |
27/06/25 | 1.75 | 1.80 | 1.60 | 1.60 | 2,905,357 |
26/06/25 | 1.80 | 1.90 | 1.74 | 1.75 | 568,556 |
25/06/25 | 1.77 | 2.04 | 1.75 | 1.80 | 2,274,334 |
24/06/25 | 1.71 | 1.78 | 1.69 | 1.77 | 186,321 |
23/06/25 | 1.68 | 1.726 | 1.65 | 1.68 | 330,881 |
20/06/25 | 1.72 | 1.725 | 1.66 | 1.705 | 354,211 |
18/06/25 | 1.70 | 1.74 | 1.65 | 1.68 | 466,429 |
17/06/25 | 1.77 | 1.775 | 1.68 | 1.69 | 448,774 |
16/06/25 | 1.84 | 1.8439 | 1.735 | 1.77 | 483,631 |
|
|
||||
|
|
||||
|
|